Regenxbio Financials

RGNX

Export CSV

Key Financial Metrics

Revenue

$83.3M

YoY-7.7%

5Y CAGR+18.8%

10Y CAGR+29.8%

Regenxbio generated $83.3M in revenue in fiscal year 2024. This represents a decrease of 7.7% from the prior year.

EBITDA

-$217.1M

YoY+13.4%

Regenxbio's EBITDA was -$217.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 13.4% from the prior year.

Free Cash Flow

-$175.6M

YoY+23.1%

Regenxbio generated -$175.6M in free cash flow in fiscal year 2024, representing cash available after capital expenditures. This represents an increase of 23.1% from the prior year.

Net Income

-$227.1M

YoY+13.8%

Regenxbio reported -$227.1M in net income in fiscal year 2024. This represents an increase of 13.8% from the prior year.

EPS (Diluted)

$-4.59

YoY+23.8%

Regenxbio earned $-4.59 per diluted share in fiscal year 2024. This represents an increase of 23.8% from the prior year.

Cash & Debt

$57.5M

YoY+66.6%

5Y CAGR-3.7%

10Y CAGR+48.3%

Regenxbio held $57.5M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

50M

YoY+12.5%

5Y CAGR+6.0%

10Y CAGR+34.0%

Regenxbio had 50M shares outstanding in fiscal year 2024. This represents an increase of 12.5% from the prior year.

Gross Margin

59.7%

YoY+1.0pp

5Y CAGR-16.9pp

10Y CAGR-38.3pp

Regenxbio's gross margin was 59.7% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 1.0 percentage points from the prior year.

Operating Margin

-280.0%

YoY+17.1pp

5Y CAGR+142.9pp

10Y CAGR-219.9pp

Regenxbio's operating margin was -280.0% in fiscal year 2024, reflecting core business profitability. This is up 17.1 percentage points from the prior year.

Net Margin

-272.5%

YoY+19.5pp

5Y CAGR-3.7pp

10Y CAGR-207.1pp

Regenxbio's net profit margin was -272.5% in fiscal year 2024, showing the share of revenue converted to profit. This is up 19.5 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$208.5M

YoY-10.2%

5Y CAGR+10.9%

10Y CAGR+45.3%

Regenxbio invested $208.5M in research and development in fiscal year 2024. This represents a decrease of 10.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$2.4M

YoY-75.5%

5Y CAGR-27.0%

Regenxbio invested $2.4M in capital expenditures in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 75.5% from the prior year.

RGNX Income Statement

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Revenue	$83.3M-7.7%	$90.2M-19.9%	$112.7M-76.0%	$470.3M+204.3%	$154.6M+338.7%	$35.2M
Cost of Revenue	$33.6M-9.8%	$37.2M-31.8%	$54.5M+5.2%	$51.8M+45.1%	$35.7M+333.4%	$8.2M
Gross Profit	$49.8M-6.2%	$53.0M-8.9%	$58.2M-86.1%	$418.5M+252.1%	$118.9M+340.3%	$27.0M
R&D Expenses	$208.5M-10.2%	$232.3M-4.2%	$242.5M+33.6%	$181.4M+9.1%	$166.3M+33.9%	$124.2M
SG&A Expenses	$76.6M-13.4%	$88.5M+3.8%	$85.3M+7.5%	$79.3M+24.3%	$63.8M+23.2%	$51.8M
Operating Income	-$233.3M+13.0%	-$268.1M-2.0%	-$262.9M-264.3%	$160.0M+234.2%	-$119.2M+20.0%	-$149.0M
Interest Expense	$12.7M+84.5%	$6.9M-70.5%	$23.3M-11.5%	$26.3M+3308.2%	$771K	N/A
Income Tax	N/A	-$152K-81.0%	-$84K-100.6%	$13.4M+155.9%	$5.2M+290.2%	-$2.8M
Net Income	-$227.1M+13.8%	-$263.5M+6.0%	-$280.3M-319.3%	$127.8M+214.9%	-$111.3M-17.4%	-$94.7M
EPS (Diluted)	$-4.59+23.8%	$-6.02+7.4%	$-6.50-323.4%	$2.91+197.7%	$-2.98-15.5%	$-2.58

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$29.7M+39.2%	$21.4M-76.0%	$89.0M	N/A	$24.2M+8.5%	$22.3M+42.7%	$15.6M	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	$12.4M+17.1%	$10.6M+147.0%	$4.3M	N/A
Gross Profit	N/A	N/A	N/A	N/A	$11.8M+0.8%	$11.7M+3.3%	$11.3M	N/A
R&D Expenses	$56.1M-5.7%	$59.5M+12.1%	$53.1M	N/A	$54.4M+11.4%	$48.9M-10.9%	$54.8M	N/A
SG&A Expenses	$20.3M+1.9%	$19.9M-2.3%	$20.3M	N/A	$19.4M+3.0%	$18.9M+3.1%	$18.3M	N/A
Operating Income	-$52.4M+17.2%	-$63.3M-621.8%	$12.1M	N/A	-$62.1M-10.8%	-$56.0M+12.3%	-$63.9M	N/A
Interest Expense	$13.2M+19.8%	$11.0M+28.3%	$8.6M	N/A	$820K+82.6%	$449K-77.2%	$2.0M	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$61.9M+12.6%	-$70.9M-1265.1%	$6.1M	N/A	-$59.6M-12.5%	-$53.0M+16.3%	-$63.3M	N/A
EPS (Diluted)	$-1.20+13.0%	$-1.38-1250.0%	$0.12	N/A	$-1.17-11.4%	$-1.05+23.9%	$-1.38	N/A

RGNX Balance Sheet

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Total Assets	$466.0M-18.8%	$574.0M-31.1%	$833.3M-25.2%	$1.1B+57.3%	$708.2M+42.2%	$497.9M
Current Assets	$278.0M-17.0%	$335.0M-19.5%	$416.0M-19.8%	$518.8M-2.3%	$531.2M+54.0%	$345.0M
Cash & Equivalents	$57.5M+66.6%	$34.5M-64.4%	$97.0M-71.9%	$345.2M+2.0%	$338.4M+386.8%	$69.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$20.5M-19.7%	$25.5M-13.8%	$29.6M-14.7%	$34.7M-25.0%	$46.3M+9.4%	$42.3M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$206.3M-21.3%	$262.2M-17.3%	$317.1M-9.3%	$349.6M+5.8%	$330.4M+592.5%	$47.7M
Current Liabilities	$103.2M-20.8%	$130.3M-0.1%	$130.4M0.0%	$130.5M+60.2%	$81.4M+141.9%	$33.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$259.7M-16.7%	$311.7M-39.6%	$516.2M-32.5%	$764.3M+102.3%	$377.8M-16.1%	$450.2M
Retained Earnings	-$932.1M-32.2%	-$705.0M-59.7%	-$441.6M-173.9%	-$161.2M+44.2%	-$289.1M-62.6%	-$177.8M

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$525.2M-9.6%	$581.0M+18.4%	$490.9M+5.4%	$466.0M-10.2%	$519.1M-8.8%	$569.4M-9.5%	$629.2M+9.6%	$574.0M
Current Assets	$332.0M-11.2%	$373.8M+19.3%	$313.2M+12.7%	$278.0M-11.3%	$313.4M-9.6%	$346.7M-12.3%	$395.4M+18.0%	$335.0M
Cash & Equivalents	$58.8M-26.1%	$79.6M-38.9%	$130.1M+126.2%	$57.5M+1.6%	$56.6M-2.0%	$57.8M-48.9%	$113.0M+227.3%	$34.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$25.3M+16.4%	$21.8M+12.3%	$19.4M-5.2%	$20.5M-14.7%	$24.0M+3.2%	$23.3M+42.3%	$16.4M-35.9%	$25.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$363.8M-1.0%	$367.3M+69.5%	$216.7M+5.0%	$206.3M-5.2%	$217.7M-1.5%	$221.1M-7.3%	$238.5M-9.0%	$262.2M
Current Liabilities	$124.6M+4.2%	$119.5M+12.0%	$106.7M+3.4%	$103.2M+0.5%	$102.7M+4.5%	$98.3M-10.8%	$110.2M-15.4%	$130.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$161.5M-24.4%	$213.7M-22.1%	$274.2M+5.6%	$259.7M-13.9%	$301.4M-13.5%	$348.3M-10.9%	$390.7M+25.3%	$311.7M
Retained Earnings	-$1.1B-6.2%	-$996.9M-7.7%	-$926.1M+0.7%	-$932.1M-5.8%	-$881.0M-7.3%	-$821.4M-6.9%	-$768.4M-9.0%	-$705.0M

RGNX Cash Flow Statement

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Operating Cash Flow	-$173.1M+20.7%	-$218.4M-5.3%	-$207.5M-194.8%	$218.9M+504.9%	-$54.1M+49.8%	-$107.7M
Capital Expenditures	$2.4M-75.5%	$10.0M-67.6%	$30.7M-63.5%	$84.2M+213.3%	$26.9M+129.3%	$11.7M
Free Cash Flow	-$175.6M+23.1%	-$228.4M+4.1%	-$238.2M-276.8%	$134.7M+266.4%	-$80.9M+32.2%	-$119.4M
Investing Cash Flow	$103.4M-45.8%	$190.9M+1700.7%	-$11.9M+97.1%	-$406.6M-431.3%	$122.8M+31.2%	$93.6M
Financing Cash Flow	$92.7M+365.1%	-$35.0M-21.2%	-$28.8M-114.8%	$195.3M-2.5%	$200.2M+2290.3%	$8.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	N/A	N/A	$33.6M	N/A	N/A	N/A	-$55.5M	N/A
Capital Expenditures	N/A	N/A	$1.0M	N/A	N/A	N/A	$557K	N/A
Free Cash Flow	N/A	N/A	$32.6M	N/A	N/A	N/A	-$56.0M	N/A
Investing Cash Flow	N/A	N/A	$44.7M	N/A	N/A	N/A	$13.2M	N/A
Financing Cash Flow	N/A	N/A	-$5.8M	N/A	N/A	N/A	$120.7M	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RGNX Financial Ratios

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Gross Margin	59.7%+1.0pp	58.8%+7.2pp	51.6%-37.4pp	89.0%+12.1pp	76.9%+0.3pp	76.6%
Operating Margin	-280.0%+17.1pp	-297.1%-63.9pp	-233.2%-267.2pp	34.0%+111.1pp	-77.1%+345.8pp	-422.9%
Net Margin	-272.5%+19.5pp	-292.0%-43.3pp	-248.7%-275.9pp	27.2%+99.2pp	-72.0%+196.9pp	-268.9%
Return on Equity	N/A	N/A	N/A	16.7%	N/A	N/A
Return on Assets	-48.7%-2.8pp	-45.9%-12.3pp	-33.6%-45.1pp	11.5%+27.2pp	-15.7%+3.3pp	-19.0%
Current Ratio	2.69+0.1	2.57-0.6	3.19-0.8	3.98-2.5	6.52-3.7	10.25
Debt-to-Equity	0.79-0.0	0.84+0.2	0.61+0.2	0.46-0.4	0.87+0.8	0.11
FCF Margin	-210.7%+42.4pp	-253.1%-41.7pp	-211.3%-240.0pp	28.6%+81.0pp	-52.4%+286.6pp	-339.0%

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	N/A	N/A	N/A	N/A	48.8%-3.7pp	52.5%-20.0pp	72.6%	N/A
Operating Margin	-176.3%+120.0pp	-296.3%-309.9pp	13.6%	N/A	-256.6%-5.2pp	-251.3%+157.5pp	-408.8%	N/A
Net Margin	-208.3%+123.5pp	-331.8%-338.6pp	6.8%	N/A	-246.3%-8.6pp	-237.7%+167.7pp	-405.4%	N/A
Return on Equity	N/A	N/A	2.2%	N/A	N/A	N/A	N/A	N/A
Return on Assets	-11.8%+0.4pp	-12.2%-13.4pp	1.2%	N/A	-11.5%-2.2pp	-9.3%+0.7pp	-10.1%	N/A
Current Ratio	2.66-0.5	3.13+0.2	2.93+0.2	2.69-0.4	3.05-0.5	3.53-0.1	3.59+1.0	2.57
Debt-to-Equity	2.25+0.5	1.72+0.9	0.790.0	0.79+0.1	0.72+0.1	0.63+0.0	0.61-0.2	0.84
FCF Margin	N/A	N/A	36.6%	N/A	N/A	N/A	-358.6%	N/A

Frequently Asked Questions

What is Regenxbio's annual revenue?

Regenxbio (RGNX) reported $83.3M in revenue for fiscal year 2024.

How fast is Regenxbio's revenue growing?

Regenxbio (RGNX) revenue declined by 7.7% year-over-year, from $90.2M to $83.3M in fiscal year 2024.

Is Regenxbio profitable?

No, Regenxbio (RGNX) reported a net income of -$227.1M in fiscal year 2024, with a net profit margin of -272.5%.

What is Regenxbio's earnings per share (EPS)?

Regenxbio (RGNX) reported diluted earnings per share of $-4.59 for fiscal year 2024.

What is Regenxbio's EBITDA?

Regenxbio (RGNX) had EBITDA of -$217.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Regenxbio's gross margin?

Regenxbio (RGNX) had a gross margin of 59.7% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Regenxbio's operating margin?

Regenxbio (RGNX) had an operating margin of -280.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Regenxbio's net profit margin?

Regenxbio (RGNX) had a net profit margin of -272.5% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Regenxbio's free cash flow?

Regenxbio (RGNX) generated -$175.6M in free cash flow during fiscal year 2024, representing cash available after capital expenditures.

What is Regenxbio's operating cash flow?

Regenxbio (RGNX) generated -$173.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Regenxbio's total assets?

Regenxbio (RGNX) had $466.0M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Regenxbio's capital expenditures?

Regenxbio (RGNX) invested $2.4M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Regenxbio spend on research and development?

Regenxbio (RGNX) invested $208.5M in research and development during fiscal year 2024.

How many shares does Regenxbio have outstanding?

Regenxbio (RGNX) had 50M shares outstanding as of fiscal year 2024.

What is Regenxbio's current ratio?

Regenxbio (RGNX) had a current ratio of 2.69 as of fiscal year 2024, which is generally considered healthy.

What is Regenxbio's debt-to-equity ratio?

Regenxbio (RGNX) had a debt-to-equity ratio of 0.79 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Regenxbio's return on assets (ROA)?

Regenxbio (RGNX) had a return on assets of -48.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.